Articles
In a head-to-head comparison for the treatment of metastatic renal cell carcinoma, pazopanib showed similar efficacy to sunitinib but was associated with fewer side effects and an increased quality of life, according to Robert Motzer, MD, of Memorial Sloan-Kettering Cancer Center, New York, who presented the COMPARZ trial at the European Society for Medical Oncology 2012 Congress, held in Vienna, Austria.
By Wayne Kuznar
Jill Drury Awarded the TOP Pharmacist Award
Animal study shows higher percentage of drug delivered to lungs via inhalation.
Novel drugs developed by UT Southwestern Medical Center researchers interrupt androgen receptor signaling.
UC Irvine researchers isolate markers for the detection of prostate cancer in urine.
An internationally collaborated study revealed a decreased risk of cancer among children whose parents lived beyond average life spans.
Brown University researchers show throat and vocal cords are better protected when heartburn is treated with antacids.
This is the third article in a 4-part series on bendamustine. While the previous article discussed the efficacy of bendamustine for patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL) in the registration studies cited in the US product labeling, this article discusses its safety
Bendamustine is an active chemotherapy agent approved by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) and for specific populations of patients with non-Hodgkin lymphoma (NHL).
Bendamustine is approved for single-agent use in chronic lymphocytic leukemia (CLL) based on the result from a phase 3 trial comparing bendamustine and chlorambucil.